Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: A mechanism for antipsychotic drug action?

American Journal of Psychiatry

Volumn 166, Issue 7, 2009, Pages 812-820

  Ghose, Subroto ^a   Gleason, Kelly A ^a   Potts, Bryan W ^a   Lewis Amezcua, Kelly ^a   Tamminga, Carol A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMATE CARBOXYPEPTIDASE II; HALOPERIDOL; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; N ACETYLASPARTYLGLUTAMIC ACID; RISPERIDONE;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN TISSUE; MOTOR CORTEX; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SCHIZOPHRENIA; TEMPORAL CORTEX;

ANIMALS; ANTIPSYCHOTIC AGENTS; BLOTTING, WESTERN; BRAIN; DISEASE MODELS, ANIMAL; HALOPERIDOL; HUMANS; MIDDLE AGED; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA;

EID: 67649981850     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2009.08091445     Document Type: Article

References (39)

1. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA: Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 2001; 25:455-467
2. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS: Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51:199-214
3. Moghaddam B, Adams BW: Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998; 281:1349-1352
4. Gao XM, Sakai K, Roberts RC, Conley RR, Dean B, Tamminga CA: Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am J Psychiatry 2000; 157:1141-1149
5. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 2007; 13:1102-1107
6. Egan MF, Straub RE, Goldberg TE, Yakub I, Callicott JH, Hariri AR, Mattay VS, Bertolino A, Hyde TM, Shannon-Weickert C, Akil M, Crook J, Vakkalanka RK, Balkissoon R, Gibbs RA, Kleinman JE, Weinberger DR: Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci U S A 2004; 101:12604-12609
7. Tan HY, Chen Q, Sust S, Buckholtz JW, Meyers JD, Egan MF, Mattay VS, Meyer-Lindenberg A, Weinberger DR, Callicott JH: Epistasis between catechol-O-methyltransferase and type II metabotropic glutamate receptor 3 genes on working memory brain function. Proc Natl Acad Sci U S A 2007; 104:12536-12541
8. Woolley ML, Pemberton DJ, Bate S, Corti C, Jones DN: The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology (Berl) 2008; 196:431-440
9. Neale JH, Bzdega T, Wroblewska B: N-acetylaspartylglutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system. J Neurochem 2000; 75:443-452
10. Olszewski RT, Wegorzewska MM, Monteiro AC, Krolikowski KA, Zhou J, Kozikowski AP, Long K, Mastropaolo J, Deutsch SI, Neale JH: Phencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors. Biol Psychiatry 2008; 63:86-91
11. Crook JM, Akil M, Law BC, Hyde TM, Kleinman JE: Comparative analysis of group II metabotropic glutamate receptor immunoreactivity in Brodmann's area 46 of the dorsolateral prefrontal cortex from patients with schizophrenia and normal subjects. Mol Psychiatry 2002; 7:157-164
12. Gupta DS, McCullumsmith RE, Beneyto M, Haroutunian V, Davis KL, Meador-Woodruff JH: Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. Synapse 2005; 57:123-131
13. González-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, López-Giménez JF, Zhou M, Okawa Y, Callado LF, Milligan G, Gingrich JA, Filizola M, Meana JJ, Sealfon SC: Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 2008; 452:93-97
14. Stan AD, Ghose S, Gao XM, Roberts RC, Lewis-Amezcua K, Hatanpaa KJ, Tamminga CA: Human postmortem tissue: What quality markers matter? Brain Res 2006; 1123:1-11
15. Gao XM, Cooper T, Suckow RF, Tamminga CA: Multidose risperidone treatment evaluated in a rodent model of tardive dyskinesia. Neuropsychopharmacology 2006; 31:1864-1868
16. Ohishi H, Neki A, Mizuno N: Distribution of a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat and mouse: an immunohistochemical study with a monoclonal antibody. Neurosci Res 1998; 30:65-82
17. Tamaru Y, Nomura S, Mizuno N, Shigemoto R: Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre- and postsynaptic sites. Neuroscience 2001; 106:481-503
18. Ghose S, Crook JM, Bartus CL, Sherman TG, Herman MM, Hyde TM, Kleinman JE, Akil M: Metabotropic glutamate receptor 2 and 3 gene expression in the human prefrontal cortex and mesencephalon in schizophrenia. Int J Neurosci 2008; 118:1609-1627
19. Callicott JH, Mattay VS, Verchinski BA, Marenco S, Egan MF, Weinberger DR: Complexity of prefrontal cortical dysfunction in schizophrenia: more than up or down. Am J Psychiatry 2003; 160:2209-2215
20. Perlstein WM, Carter CS, Noll DC, Cohen JD: Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia. Am J Psychiatry 2001; 158:1105-1113
21. Harrison PJ, Weinberger DR: Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005; 10:40-68; image 5
22. Olszewski RT, Bukhari N, Zhou J, Kozikowski AP, Wroblewski JT, Shamimi-Noori S, Wroblewska B, Bzdega T, Vicini S, Barton FB, Neale JH: NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. J Neurochem 2004; 89:876-885
23. Ghose S, Weickert CS, Colvin SM, Coyle JT, Herman MM, Hyde TM, Kleinman JE: Glutamate carboxypeptidase II gene expression in the human frontal and temporal lobe in schizophrenia. Neuropsychopharmacology 2004; 29:117-125
24. Guilarte TR, Hammoud DA, McGlothan JL, Caffo BS, Foss CA, Kozikowski AP, Pomper MG: Dysregulation of glutamate carboxypeptidase II in psychiatric disease. Schizophr Res 2008; 99:324-332
25. Tsai G, Passani LA, Slusher BS, Carter R, Baer L, Kleinman JE, Coyle JT: Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 1995; 52:829-836
26. Ohnuma T, Augood SJ, Arai H, McKenna PJ, Emson PC: Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Brain Res Mol Brain Res 1998; 56:207-217
27. Sartorius LJ, Weinberger DR, Hyde TM, Harrison PJ, Kleinman JE, Lipska BK: Expression of a GRM3 splice variant is increased in the dorsolateral prefrontal cortex of individuals carrying a schizophrenia risk SNP. Neuropsychopharmacology 2008; 33:2626-2634
28. Corti C, Crepaldi L, Mion S, Roth AL, Xuereb JH, Ferraguti F: Altered dimerization of metabotropic glutamate receptor 3 in schizophrenia. Biol Psychiatry 2007; 62:747-755
29. Flores C, Coyle JT: Regulation of glutamate carboxypeptidase II function in corticolimbic regions of rat brain by phencyclidine, haloperidol, and clozapine. Neuropsychopharmacology 2003; 28:1227-1234
30. Petralia RS, Wang YX, Niedzielski AS, Wenthold RJ: The metabotropic glutamate receptors, mGluR2 and mGluR3, show unique postsynaptic, presynaptic and glial localizations. Neuroscience 1996; 71:949-976
31. Homayoun H, Jackson ME, Moghaddam B: Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats. J Neurophysiol 2005; 93:1989-2001
32. Ghose S, Wroblewska B, Corsi L, Grayson DR, De Blas AL, Vicini S, Neale JH: N-acetylaspartylglutamate stimulates metabotropic glutamate receptor 3 to regulate expression of the GABA(A) alpha6 subunit in cerebellar granule cells. J Neurochem 1997; 69:2326-2335
33. Hashimoto T, Arion D, Unger T, Maldonado-Aviles JG, Morris HM, Volk DW, Mirnics K, Lewis DA: Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 2008; 13:147-161
34. Bruno V, Battaglia G, Casabona G, Copani A, Caciagli F, Nicoletti F: Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-beta. J Neurosci 1998; 18:9594-9600
35. 2 modulates synaptic efficacy and plasticity and induces phosphorylation of CREB in hippocampal neurons. Hippocampus 2007; 17:5-9
36. Kurisaki A, Inoue I, Kurisaki K, Yamakawa N, Tsuchida K, Sugino H: Activin induces long-lasting N-methyl-D-aspartate receptor activation via scaffolding PDZ protein activin receptor interacting protein 1. Neuroscience 2008; 151:1225-1235
37. Esquenazi S, Monnerie H, Kaplan P, Le Roux P: BMP-7 and excess glutamate: opposing effects on dendrite growth from cerebral cortical neurons in vitro. Exp Neurol 2002; 176:41-54
38. Baslow MH, Dyakin VV, Nowak KL, Hungund BL, Guilfoyle DN: 2-PMPA, a NAAG peptidase inhibitor, attenuates magnetic resonance BOLD signals in brain of anesthetized mice: evidence of a link between neuron NAAG release and hyperemia. J Mol Neurosci 2005; 26:1-15
39. Hill K, Mann L, Laws KR, Stephenson CM, Nimmo-Smith I, McKenna PJ: Hypofrontality in schizophrenia: a meta-analysis of functional imaging studies. Acta Psychiatr Scand 2004; 110:243-256